P3 Health Partners Inc. PIII
7.05
0.00
0.00%
as of 25 Sep
- Market cap
- $51.2M
- P/E
- 0.0×
Follow PIII
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.02 | 0.01 | 0.01 | 0.02 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(1.90) | (0.44) | (0.37) | (0.59) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.17 | 0.18 | 0.20 | 0.09 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.99) | (2.84) | (3.47) | (1.03) | |
EV/FCF |
(1.96) | (2.84) | (3.47) | (1.03) | |
Quick Ratio |
0.29 | 0.22 | 0.30 | 0.43 | |
Current Ratio |
0.32 | 0.24 | 0.33 | 0.46 | |
Net Debt/EBITDA |
(17.56) | (1.89) | 8.90 | 1.56 | |
Debt/Assets |
37.00% | 41.64% | 46.26% | 18.38% | |
Debt/Equity |
(13.53) | (1.76) | (2.17) | 1.64 | |
Asset Turnover |
1.91 | 2.03 | 2.02 | 2.17 | |
Operating CF/Net income |
0.49 | 0.34 | (22.46) | 29.12 | |
Capex/Depreciation |
0.00 | 0.01 | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
6.49% | 9.41% | 6.67% | 8.38% | |
Intangible Assets out of Total Assets |
0.75 | 0.75 | 0.70 | 0.69 | |
Share Based Compensation of Revenue |
0.35% | 0.29% | 0.27% | 0.22% | |
Graham Net Nets |
(19.37) | (59.50) | (63.74) | (11.07) | |
Graham Number |
71.90 | 219.76 | 194.60 | 141.85 | |
Earnings Yield |
(448.94%) | (1,295.13%) | (1,251.62%) | (305.09%) | |
Free Cash Flow Yield |
(424.74%) | (800.56%) | (842.65%) | (359.73%) | |
Revenue per Share |
105.65 | 117.72 | 117.52 | 114.93 | |
Operating CF per Share |
(4.72) | (7.87) | (8.35) | (18.42) | |
Capex per Share |
(0.04) | 0.06 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(4.75) | (7.81) | (8.35) | (18.42) | |
Cash per Share |
11.77 | 7.89 | 7.94 | 6.60 | |
Shareholders Equity per Share |
(5.72) | (47.49) | (43.66) | 21.77 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(5.72) | (47.49) | (43.66) | 21.77 | |
Free Cash Flow |
(15.53) | (25.53) | (27.47) | (61.91) | |
Working Capital |
(288.32) | (412.17) | (353.27) | (209.24) | |
Capital Expenditures |
(0.12) | 0.20 | — | — | |
Net Current Asset Value |
(566.62) | (678.79) | (645.49) | (401.86) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(9.15%) | (19.62%) | 0.32% | (0.55%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
105.79 | 110.53 | 134.36 | 122.83 | |
Average Payables |
301.22 | 344.22 | 341.35 | 280.12 | |
Average Assets |
758.45 | 720.03 | 729.01 | 692.99 | |
Average Common Equity |
50.91 | (39.65) | (40.15) | (23.39) |
Columns are period end dates